Literature DB >> 11960887

Pathological, clinical and genetic heterogeneity in progressive supranuclear palsy.

H R Morris1, G Gibb, R Katzenschlager, N W Wood, D P Hanger, C Strand, T Lashley, S E Daniel, A J Lees, B H Anderton, T Revesz.   

Abstract

We have identified two groups of patients with clinically typical and atypical, pathologically diagnosed progressive supranuclear palsy (PSP), and investigated their genetic and molecular pathological characteristics. Those with clinically typical PSP are more likely to have the PSP susceptibility genotype and to have the deposition of PSP-type hyperphosphorylated tau protein. The clinically atypical PSP group contains a number of different clinical syndromes, including an L-dopa unresponsive bradykinetic syndrome and a clinical syndrome closely resembling idiopathic Parkinson's disease. The clinically atypical PSP group are less likely to have the PSP susceptibility genotype and often have the deposition of Alzheimer's disease paired helical filament type hyperphosphorylated tau. This study suggests that the tau PSP susceptibility genotype is most strongly associated with clinically typical PSP. Neurofibrillary tangle parkinsonian disorders, which pathologically resemble PSP but involve the deposition of Alzheimer's disease-type tau often without involvement of the tau susceptibility genotype, need to be distinguished for diagnostic and research purposes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11960887     DOI: 10.1093/brain/awf109

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  14 in total

1.  In vivo evaluation of white matter pathology in patients of progressive supranuclear palsy using TBSS.

Authors:  Jitender Saini; Bhavani Shankara Bagepally; Mangalore Sandhya; Shaik Afsar Pasha; Ravi Yadav; Pramod Kumar Pal
Journal:  Neuroradiology       Date:  2011-12-09       Impact factor: 2.804

2.  Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy.

Authors:  Farwa Ali; Peter R Martin; Hugo Botha; J Eric Ahlskog; James H Bower; Joseph Y Masumoto; Demetrius Maraganore; Anhar Hassan; Scott Eggers; Bradley F Boeve; David S Knopman; Daniel Drubach; Ronald C Petersen; Erika Driver Dunkley; Jay van Gerpen; Ryan Uitti; Jennifer L Whitwell; Dennis W Dickson; Keith A Josephs
Journal:  Mov Disord       Date:  2019-02-06       Impact factor: 10.338

3.  Hypokinesia without decrement distinguishes progressive supranuclear palsy from Parkinson's disease.

Authors:  Helen Ling; Luke A Massey; Andrew J Lees; Peter Brown; Brian L Day
Journal:  Brain       Date:  2012-03-06       Impact factor: 13.501

Review 4.  Gray matter atrophy in progressive supranuclear palsy: meta-analysis of voxel-based morphometry studies.

Authors:  Hai Cun Shi; Jian Guo Zhong; Ping Lei Pan; Pei Rong Xiao; Yuan Shen; Li Juan Wu; Hua Liang Li; Yuan Ying Song; Gui Xiang He; Hong Ye Li
Journal:  Neurol Sci       Date:  2013-03-30       Impact factor: 3.307

5.  How does the genetic assassin select its neuronal target?

Authors:  James C Stevens; Elizabeth M C Fisher; Simon Mead
Journal:  Mamm Genome       Date:  2011-03-04       Impact factor: 2.957

6.  Saccade abnormalities in autopsy-confirmed frontotemporal lobar degeneration and Alzheimer disease.

Authors:  Adam L Boxer; Siobhan Garbutt; William W Seeley; Aria Jafari; Hilary W Heuer; Jacob Mirsky; Joanna Hellmuth; John Q Trojanowski; Erik Huang; Steven DeArmond; John Neuhaus; Bruce L Miller
Journal:  Arch Neurol       Date:  2012-04

7.  Voxel-based morphometry in autopsy proven PSP and CBD.

Authors:  Keith A Josephs; Jennifer L Whitwell; Dennis W Dickson; Bradley F Boeve; David S Knopman; Ronald C Petersen; Joseph E Parisi; Clifford R Jack
Journal:  Neurobiol Aging       Date:  2006-11-13       Impact factor: 4.673

8.  Glycolitic enzymes are targets of oxidation in aged human frontal cortex and oxidative damage of these proteins is increased in progressive supranuclear palsy.

Authors:  A Martínez; E Dalfó; G Muntané; I Ferrer
Journal:  J Neural Transm (Vienna)       Date:  2007-08-21       Impact factor: 3.575

9.  Clinical outcomes of two main variants of progressive supranuclear palsy and multiple system atrophy: a prospective natural history study.

Authors:  Milica Jecmenica-Lukic; Igor N Petrovic; Tatjana Pekmezovic; Vladimir S Kostic
Journal:  J Neurol       Date:  2014-06-03       Impact factor: 4.849

10.  Utility of the Movement Disorders Society Criteria for Progressive Supranuclear Palsy in Clinical Practice.

Authors:  Farwa Ali; Hugo Botha; Jennifer L Whitwell; Keith A Josephs
Journal:  Mov Disord Clin Pract       Date:  2019-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.